Comparative Pharmacology
Head-to-head clinical analysis: PFIZERPEN VK versus PFIZERPEN AS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PFIZERPEN VK versus PFIZERPEN AS.
PFIZERPEN VK vs PFIZERPEN-AS
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
PFIZERPEN-AS (penicillin G procaine) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and transglycosylation, leading to cell lysis.
Treatment of mild to moderate infections caused by susceptible gram-positive cocci (e.g., Streptococcus pyogenes, Streptococcus pneumoniae, susceptible staphylococci)Prophylaxis of rheumatic fever recurrenceOff-label: Treatment of erysipeloid, anthrax (cutaneous, post-exposure), clostridial infectionsOff-label: Periodontal infections (in combination with metronidazole)
Moderate to severe infections caused by penicillin-sensitive microorganisms (e.g., streptococcal, pneumococcal, gonococcal infections)Syphilis (primary, secondary, and latent)Anthrax (post-exposure prophylaxis)Rat-bite feverOff-label: Neurosyphilis (with probenecid)Off-label: Endocarditis prophylaxis
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections. For group A streptococcal pharyngitis: 250 mg orally 3 times daily or 500 mg twice daily for 10 days.
250-500 mg orally every 6-8 hours for moderate infections; 500 mg to 2 g intravenously every 4-6 hours for severe infections.
None Documented
None Documented
Terminal half-life: 30–60 minutes in adults with normal renal function; prolonged in renal impairment (up to 4–10 hours in anuria).
0.5-1 hour in healthy adults; prolonged to 2.5-10 hours in renal impairment (CrCl <10 mL/min). Clinically relevant for dosing interval adjustment in renal dysfunction.
Primarily excreted unchanged in urine via renal tubular secretion; minor hepatic metabolism to inactive metabolites (penicilloic acid).
Hepatic metabolism (minor); primarily renal elimination via glomerular filtration and tubular secretion (unchanged drug).
Renal: ~60-80% unchanged via tubular secretion; biliary/fecal: minor (hepatic elimination of metabolites).
Primarily renal (60-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal elimination (10-20%)
~80% bound, primarily to serum albumin.
50-65% primarily to serum albumin
0.3–0.5 L/kg (approx. 20–40 L in adults); limited distribution into CNS except with inflamed meninges.
0.3-0.4 L/kg; low Vd indicating limited extravascular distribution. Increased in neonates, pregnancy, and inflammatory states.
Oral: approximately 60–75% (variable, reduced by food); IM: nearly complete (~100%).
IM: 70-100%; Oral: 30-60% (variable due to gastric acid degradation). IV: 100%
CrCl >30 mL/min: no adjustment. CrCl 10-30 mL/min: administer every 8-12 hours. CrCl <10 mL/min: administer every 12-18 hours. For anuria: avoid use or reduce dose to 250 mg every 12 hours.
CrCl 10-50 mL/min: administer every 8-12 hours; CrCl <10 mL/min: administer every 12-18 hours; hemodialysis: supplement dose after dialysis.
No specific Child-Pugh based adjustments required; monitor for hepatic adverse effects. No dose modification recommended in hepatic impairment.
No dosage adjustment required for mild to moderate hepatic impairment; caution in severe impairment due to potential accumulation.
Children >12 years: adult dosing. Infants and children <12 years: 25-50 mg/kg/day orally divided every 6-8 hours; maximum 3 g/day. For group A streptococcal pharyngitis: 25-50 mg/kg/day divided every 12 hours for 10 days.
Children >12 years: same as adult; children 1 month to 12 years: 25-50 mg/kg/day orally divided every 6-8 hours; intravenous: 100-200 mg/kg/day divided every 4-6 hours; neonates: 50 mg/kg per dose intramuscularly or intravenously every 12 hours for first week of life, then every 8 hours.
No specific dose adjustment; use with caution due to age-related renal decline. Monitor renal function and adjust based on CrCl. Increased risk of adverse effects (e.g., seizures with high doses).
Use lowest effective dose; monitor renal function and adjust based on CrCl; increased risk of neurotoxicity (seizures) with high doses.
No FDA black box warning.
Severe and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported. Some patients have a history of penicillin hypersensitivity but others have had no prior history. Emergency measures including epinephrine, corticosteroids, and airway management must be immediately available.
["Serious hypersensitivity reactions (anaphylaxis) may occur, especially in patients with penicillin allergy","Use caution in renal impairment (CrCl <10 mL/min) due to risk of neurotoxicity with high doses","Pseudomembranous colitis associated with C. difficile may occur","Prolonged use may predispose to superinfection","Assess renal function periodically in prolonged therapy"]
["Severe hypersensitivity reactions including anaphylaxis","CNS toxicity (e.g., seizures) with high doses or renal impairment","Local reactions (e.g., procaine-induced neuropsychiatric reactions)","Risk of C. difficile-associated diarrhea","Renal impairment: dose adjustment may be required","Superinfection with prolonged use"]
["Hypersensitivity to penicillins or any component of the formulation","Previous history of immediate hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to beta-lactams"]
["Hypersensitivity to penicillins or procaine","Previous immediate-type hypersensitivity reaction (e.g., anaphylaxis) to cephalosporins or other beta-lactams"]
Data Pending Review
Data Pending Review
Avoid taking with food, especially high-fiber or high-fat meals, as they reduce absorption. Avoid acidic beverages (e.g., fruit juices, colas) which may degrade the drug. Take with a full glass of water.
No clinically significant food interactions. However, patients on prolonged therapy should maintain adequate hydration. No dietary restrictions required.
Penicillin VK (phenoxymethylpenicillin) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and no adequate human studies exist for first trimester. However, penicillin VK is considered safe throughout pregnancy when clinically indicated. No known teratogenicity. Risk of neonatal coagulopathy if maternal administration near term due to gut flora alteration, but not directly teratogenic.
Pfizerpen-AS (penicillin G procaine) is classified as FDA pregnancy category B. Animal studies have not demonstrated teratogenic effects. In humans, penicillins are generally considered safe during pregnancy with no established risk of congenital anomalies. First trimester: No evidence of increased malformations. Second/third trimesters: No known fetal harm. However, use only if clearly needed.
Penicillin VK is excreted into breast milk in small amounts (M/P ratio approximately 0.1-0.2). Levels are unlikely to cause adverse effects in the infant. Risk of diarrhea, candidiasis, or allergic sensitization. Considered compatible with breastfeeding by the American Academy of Pediatrics.
Penicillin G is excreted into breast milk in low concentrations (M/P ratio approximately 0.2). It is considered compatible with breastfeeding by the American Academy of Pediatrics. Potential risks include alteration of infant gut flora and allergic sensitization. Use with caution in infants with known penicillin allergy.
No dose adjustment typically required in pregnancy. However, increased plasma volume and renal clearance may slightly reduce serum levels, but clinical significance is minimal. Standard dosing is adequate for most pregnant patients. For severe infections, consider higher doses if necessary.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may require dose adjustments. Standard dosing may be insufficient for serious infections; consider higher doses or more frequent administration. Therapeutic drug monitoring (e.g., serum drug levels) is recommended for severe infections to ensure adequate exposure. No specific guidelines; adjust based on clinical response and infection severity.
Category C
Category C
PFIZERPEN VK (penicillin V potassium) is a narrow-spectrum penicillinase-sensitive penicillin. It is the drug of choice for group A streptococcal pharyngitis and for prophylaxis of rheumatic fever. It is acid-stable and can be given orally, but absorption is impaired by food. Dosing should be adjusted for renal impairment (CrCl <10 mL/min, dose every 12 hours). It has poor activity against H. influenzae and is not reliable for serious staphylococcal infections. Allergy cross-reactivity with cephalosporins is rare but possible.
PFIZERPEN-AS (aqueous penicillin G procaine) is a long-acting intramuscular formulation; avoid intravenous administration. Always confirm absence of penicillin allergy before administration; obtain culture and sensitivity prior to initiation for confirmed bacterial infections. Monitor for procaine reactions (psychomotor agitation, seizures) and anaphylaxis. Do not use for neurosyphilis; use aqueous crystalline penicillin G instead. In renal impairment (CrCl <10 mL/min), dosing interval may be extended to 24 hours.
Take on an empty stomach (1 hour before or 2 hours after meals) for best absorption.Complete the full course even if you feel better to prevent resistance.If a dose is missed, take it as soon as possible; if near next dose, skip the missed dose. Do not double dose.Common side effects include nausea, vomiting, diarrhea, and rash. Contact doctor if severe diarrhea or allergic symptoms occur.Do not take with acidic beverages like fruit juices or sodas; take with water.Inform clinician about any kidney disease or history of allergies.
This medication is given as a deep intramuscular injection, usually into the buttock or thigh; do not massage the injection site.Report any signs of allergic reaction (rash, hives, difficulty breathing, swelling of lips/face) immediately.Complete the full course even if you feel better; inform your doctor if you have a history of penicillin allergy.Possible injection site pain, tenderness, or redness may occur. Seek medical attention if severe pain, swelling, or drainage develops.Avoid driving or operating machinery if you experience dizziness, confusion, or seizure-like symptoms (procaine reaction).